MarketPeel
Insider Trading Intelligence
Pricing
…
JF

Jean Francois Formela

NTLA
DIRECTOR · INTELLIA THERAPEUTICS, INC. · CIK 0001030575
FILING MIX · LIFETIME25%/75%
BUYS
15
SELLS
44
TOTAL VALUE
$154.74M
COMPANIES
3
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
184,858
AVG SELL PX
$86.37
TRADE KIND
SHOWING 59 / 59
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
34 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Jean Francois Formela, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d34+47.06%+0.02%+0.46%-0.44%+10.73%-0.21
14d34+23.53%+8.29%+1.23%+7.05%+8.69%1.82
30d34+23.53%+11.30%+2.32%+8.98%-0.61%1.89
60d34+2.94%+33.27%+4.79%+28.47%+14.58%6.01
90d34+0.00%+37.28%+4.89%+32.39%+6.72%6.12
180d34+52.94%+22.17%+10.85%+11.33%-15.80%1.84
1y34+97.06%-50.74%-5.94%-44.80%-51.32%-15.93
2y34+100.00%-60.56%+4.65%-65.21%-73.65%-39.95
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NTLA · 7,688 shares · as of Jun 14, 2022
0278,344556,688835,0321,113,37620212022SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 15 buys / 44 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KRRO
KORRO BIO, INC.
SALE10b5-1
10b5-1 plan
666$14.98$10.0K793,328Jun 24, 2026Jun 24, 2026 ↗View →
KRRO
KORRO BIO, INC.
SALE10b5-1
10b5-1 plan
40,679$14.60$593.9K793,994Jun 24, 2026Jun 24, 2026 ↗View →
KRRO
KORRO BIO, INC.
SALE10b5-1
10b5-1 plan
6,979$14.60$101.9K169,670Jun 24, 2026Jun 24, 2026 ↗View →
KRRO
KORRO BIO, INC.
SALE10b5-1
10b5-1 plan
114$14.98$1.7K169,556Jun 24, 2026Jun 24, 2026 ↗View →
KRRO
KORRO BIO, INC.
SALE10b5-1
10b5-1 plan
101,579$14.25$1.45M834,673Jun 23, 2026Jun 24, 2026 ↗View →
KRRO
KORRO BIO, INC.
SALE10b5-1
10b5-1 plan
17,426$14.25$248.3K176,649Jun 23, 2026Jun 24, 2026 ↗View →
KRRO
KORRO BIO, INC.
SALE10b5-1
10b5-1 plan
3,382$13.95$47.2K936,252Jun 22, 2026Jun 24, 2026 ↗View →
KRRO
KORRO BIO, INC.
SALE10b5-1
10b5-1 plan
580$13.95$8.1K194,075Jun 22, 2026Jun 24, 2026 ↗View →
KRRO
KORRO BIO, INC.
PURCHASEGRANT
Stock grant
14,677——14,677Jun 10, 2026Jun 11, 2026 ↗View →
KRRO
KORRO BIO, INC.
SALE10b5-1
10b5-1 plan
2,441$13.95$34.1K939,634May 28, 2026Jun 1, 2026 ↗View →
KRRO
KORRO BIO, INC.
SALE10b5-1
10b5-1 plan
419$13.95$5.8K194,655May 28, 2026Jun 1, 2026 ↗View →
KRRO
KORRO BIO, INC.
PURCHASEGRANT
Stock grant
6,010——6,010Jun 11, 2025Jun 12, 2025 ↗View →
KRRO
KORRO BIO, INC.
PURCHASEGRANT
Stock grant
5,190——5,190Jun 11, 2024Jun 12, 2024 ↗View →
KRRO
KORRO BIO, INC.
PURCHASEGRANT
Stock grant
17,857$56.00$1000.0K195,074Apr 22, 2024Apr 23, 2024 ↗View →
KRRO
KORRO BIO, INC.
PURCHASEGRANT
Stock grant
16,000——16,000Nov 3, 2023Nov 7, 2023 ↗View →
KRRO
KORRO BIO, INC.
PURCHASEGRANT
Stock grant
942,075——942,075Nov 3, 2023Nov 7, 2023 ↗View →
KRRO
KORRO BIO, INC.
PURCHASEGRANT
Stock grant
177,217——177,217Nov 3, 2023Nov 7, 2023 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,197——7,291Jun 14, 2022Jun 16, 2022 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,688——7,688Jun 14, 2022Jun 16, 2022 ↗View →
SPRO
SPERO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,500——7,500Aug 17, 2021Aug 18, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
55,525$127.79$7.10M481,832Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
6,149$143.45$882.1K10,000Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
56,188$132.77$7.46M200,349Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
36,519$133.77$4.89M163,830Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
5,400$138.05$745.5K102,673Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
26,019$127.02$3.30M537,357Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
8,420$141.66$1.19M29,705Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
53,823$131.82$7.09M256,537Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
8,027$140.80$1.13M38,125Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
21,893$135.83$2.97M111,106Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
13,556$142.88$1.94M16,149Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
48,724$129.88$6.33M376,828Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
30,831$134.86$4.16M132,999Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
4,201$138.58$582.2K98,472Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
56,280$128.77$7.25M425,552Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
52,320$139.96$7.32M46,152Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
66,468$130.79$8.69M310,360Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
3,033$137.01$415.6K108,073Jun 28, 2021Jun 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,094——2,094Jun 23, 2021Jun 25, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,382——3,382Jun 23, 2021Jun 25, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
653$89.25$58.3K563,376Jun 14, 2021Jun 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
16,293$85.92$1.40M717,862Jun 14, 2021Jun 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
93,102$87.75$8.17M577,338Jun 14, 2021Jun 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
47,422$86.73$4.11M670,440Jun 14, 2021Jun 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
13,309$88.70$1.18M564,029Jun 14, 2021Jun 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
1,875$85.98$161.2K734,155Jun 11, 2021Jun 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
29,071$85.18$2.48M736,030Jun 11, 2021Jun 15, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
4,513$85.43$385.5K765,101Apr 29, 2021Apr 30, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
29,740$86.12$2.56M769,614Apr 28, 2021Apr 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
102,186$85.40$8.73M799,354Apr 28, 2021Apr 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
79,714$85.39$6.81M1,032,056Apr 27, 2021Apr 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
68,836$86.41$5.95M963,220Apr 27, 2021Apr 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
61,680$87.08$5.37M901,540Apr 27, 2021Apr 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
806$84.93$68.5K1,111,770Apr 26, 2021Apr 28, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
800$84.98$68.0K1,112,576Apr 5, 2021Apr 7, 2021 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
SALE
501,945$60.29$30.26M1,113,376Feb 26, 2021Mar 1, 2021 ↗View →
SPRO
SPERO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,500——7,500Oct 27, 2020Oct 27, 2020 ↗View →
NTLA
INTELLIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
19,000——19,000Jun 18, 2020Jun 19, 2020 ↗View →
SPRO
SPERO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,408$6.47$35.0K5,408Jan 2, 2020Jan 6, 2020 ↗View →
Other insiders · NTLA
Loading peer insiders…
About this filer
CIK 0001030575
ROLE
Director
PRIMARY
NTLA
COMPANIES
3
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001030575DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback